These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Critical study on taraxeine]. Bury JA Encephale; 1969; 58(1):69-94. PubMed ID: 4989013 [No Abstract] [Full Text] [Related]
27. CLINICAL SYNDROMES AND BIOCHEMICAL ALTERATIONS FOLLOWING MESCALINE, LYSERGIC ACID DIETHYLAMIDE, PSILOCYBIN AND A COMBINATION OF THE THREE PSYCHOTOMIMETIC DRUGS. HOLLISTER LE; SJOBERG BM Compr Psychiatry; 1964 Jun; 5():170-8. PubMed ID: 14156873 [No Abstract] [Full Text] [Related]
28. Environmental influences upon drug-induced suppression of operant behavior. Sparber SB; Tilson HA J Pharmacol Exp Ther; 1971 Oct; 179(1):1-9. PubMed ID: 5096565 [No Abstract] [Full Text] [Related]
29. [Psycho-dysleptics]. Polvan O Turk Tip Cemiy Mecm; 1966 Nov; 32(11):661-70. PubMed ID: 5979072 [No Abstract] [Full Text] [Related]
30. [Experimental contribution to the problem of possible crossed tolerance between psychotic drugs of different structure]. MISSERE G; TONINI G Boll Soc Ital Biol Sper; 1959 Sep; 35():1119-20. PubMed ID: 14422940 [No Abstract] [Full Text] [Related]
31. Cumulative alterations in rat behavior during continuous administration of LSD or mescaline: absence of tolerance? Ellison G; Ring M; Ross D; Axelrood B Biol Psychiatry; 1980 Feb; 15(1):95-102. PubMed ID: 7357060 [TBL] [Abstract][Full Text] [Related]
32. [Various psychodysleptic substances]. Bernik V Rev Paul Med; 1972 Aug; 80(2):115-7. PubMed ID: 4671580 [No Abstract] [Full Text] [Related]
33. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. Colpaert FC; Niemegeers CJ; Janssen PA J Pharmacol Exp Ther; 1982 Apr; 221(1):206-14. PubMed ID: 7062283 [No Abstract] [Full Text] [Related]
34. Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures. HOLLISTER LE; HARTMAN AM Compr Psychiatry; 1962 Aug; 3():235-42. PubMed ID: 13908449 [No Abstract] [Full Text] [Related]
35. [Sensory deprivation and psychodysleptic activity]. Roche M C R Seances Soc Biol Fil; 1970; 164(8):1756-62. PubMed ID: 4253202 [No Abstract] [Full Text] [Related]
36. Hallucinogens and dominance behavior of the rat. Uyeno ET Proc West Pharmacol Soc; 1967; 10():94. PubMed ID: 6055511 [No Abstract] [Full Text] [Related]
37. The effect of LSD, mescaline, and D-amphetamine on the evoked "secondary discharge". Roth WT Psychopharmacologia; 1966; 9(3):253-8. PubMed ID: 6010545 [No Abstract] [Full Text] [Related]
38. Facilitation of avoidance behaviour by LSD-25 and mescaline in hamsters. Sansone M; Castellano C; Messeri P Pharmacol Res Commun; 1974 Aug; 6(4):369-76. PubMed ID: 4438404 [No Abstract] [Full Text] [Related]
39. The pharmacology of mescaline and D-lysergic acid diethylamide (LSD). KOELLE GB N Engl J Med; 1958 Jan; 258(1):25-32. PubMed ID: 13493730 [No Abstract] [Full Text] [Related]
40. Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli. Aghajanian GK Brain Res; 1980 Mar; 186(2):492-8. PubMed ID: 7357465 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]